Liposomal siRNA nanocarriers for cancer therapy

Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888 Hammond, 2000, An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells, Nature, 404, 293, 10.1038/35005107 Elbashir, 2001, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature, 411, 494, 10.1038/35078107 Hannon, 2004, Unlocking the potential of the human genome with RNA interference, Nature, 431, 371, 10.1038/nature02870 Merritt, 2008, Dicer, Drosha, and outcomes in patients with ovarian cancer, N. Engl. J. Med., 359, 2641, 10.1056/NEJMoa0803785 Petros, 2010, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discov., 9, 615, 10.1038/nrd2591 Burnett, 2012, Rossi JJ RNA-based therapeutics: current progress and future prospects, Chem. Biol., 19, 60, 10.1016/j.chembiol.2011.12.008 Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429 Ozpolat, 2010, Nanomedicine based approaches for the delivery of siRNA in cancer, J. Intern. Med., 267, 44, 10.1111/j.1365-2796.2009.02191.x Zhou, 2013, Nanoparticle-based delivery of RNAi therapeutics: progress and challenges, Pharmaceuticals (Basel), 6, 85, 10.3390/ph6010085 Minakuchi, 2004, Atelocollagen-mediated synthetic siRNA delivery for effective gene silencing in vitro and in vivo, Nucleic Acids Res., 32, e109, 10.1093/nar/gnh093 Tan, 2007, Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference, Biomaterials, 28, 1565, 10.1016/j.biomaterials.2006.11.018 Lee, 2009, All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery, Angew. Chem. Int. Ed. Engl., 48, 4174, 10.1002/anie.200805998 Yu, 2005, Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo, J. Control. Release, 110, 90, 10.1016/j.jconrel.2005.09.050 Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumorvasculature: the key role of tumor-selective macromolecular drug targeting, Adv. Enzym. Regul., 41, 189, 10.1016/S0065-2571(00)00013-3 K. Gerish, Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target 15(7–8), 457–464. Landen, 2005, Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery, Cancer Res., 65, 6910, 10.1158/0008-5472.CAN-05-0530 Miller, 1998, Liposome–cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes, Biochemistry, 37, 12875, 10.1021/bi980096y Dokka, 2000, Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes, Pharm. Res., 17, 521, 10.1023/A:1007504613351 Spagnou, 2004, Lipid carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA, Biochemistry, 43, 13348, 10.1021/bi048950a Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J. Control. Release, 114, 100, 10.1016/j.jconrel.2006.04.014 Filion, 1997, Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells, Biochim. Biophys. Acta, 1329, 345, 10.1016/S0005-2736(97)00126-0 Filion, 1998, Major limitations in the use of cationic liposomes for DNA delivery, Int. J. Pharm., 162, 159, 10.1016/S0378-5173(97)00423-7 Zimmermann, 2006, RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 10.1038/nature04688 Kim, 2008, Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA, Mol. Pharm., 5, 622, 10.1021/mp8000233 Halder, 2006, Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy, Clin. Cancer Res., 12, 4916, 10.1158/1078-0432.CCR-06-0021 Gray, 2008, Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver, J. Natl. Cancer Inst., 100, 109, 10.1093/jnci/djm279 Merritt, 2008, Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth, J. Natl. Cancer Inst., 100, 359, 10.1093/jnci/djn024 Tekedereli, 2013, Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (−) and ER (+) breast cancer, Mol. Ther. Nucleic Acids, 9/2013 Nick, 2011, Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death, J. Natl. Cancer Inst., 103, 1596, 10.1093/jnci/djr372 Pan, 2008, Nuclear factor-kappaBp65 ⁄ relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells, Clin. Cancer Res., 14, 8143, 10.1158/1078-0432.CCR-08-1539 Shao, 2012, Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors, Clin. Cancer Res., 18, 6648, 10.1158/1078-0432.CCR-12-2715 Villares, 2008, Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA, Cancer Res., 68, 9078, 10.1158/0008-5472.CAN-08-2397 Akinc, 2008, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat. Biotechnol., 26, 561, 10.1038/nbt1402 Wolfrum, 2007, Mechanisms and optimization of in vivo delivery of lipophilic siRNAs, Nat. Biotechnol., 25, 1149, 10.1038/nbt1339 Davis, 2010, Evidence of RNAi in humans from systemically adminstered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956 Heidel, 2007, Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA, Proc. Natl. Acad. Sci. U. S. A., 104, 5715, 10.1073/pnas.0701458104 Park, 1995, Development of anti-p185HER2 immunoliposomes for cancer therapy, Proc. Natl. Acad. Sci. U. S. A., 92, 1327, 10.1073/pnas.92.5.1327 Kalli, 2008, Folate receptor alpha as a tumor target in epithelial ovarian cancer, Gynecol. Oncol., 108, 619, 10.1016/j.ygyno.2007.11.020 Kim, 2006, Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI–PEG–FOL conjugate, Bioconjug. Chem., 17, 241, 10.1021/bc050289f Yoshizawa, 2008, Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts, Eur. J. Pharm. Biopharm., 70, 718, 10.1016/j.ejpb.2008.06.026 Stephenson, 2003, Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy, Anticancer Res., 23, 3341 Fattal, 2006, Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA, Adv. Drug Deliv. Rev., 58, 1203, 10.1016/j.addr.2006.07.020 Anabousi, 2006, In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer, Eur. J. Pharm. Sci., 29, 367, 10.1016/j.ejps.2006.07.004 Derycke, 2004, Transferrin-conjugated liposome targeting of the photosensitizer AlPcS4 to rat bladder carcinoma cells, J. Natl. Cancer Inst., 96, 1620, 10.1093/jnci/djh314 Qin, 2007, Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain, Chem. Pharm. Bull., 55, 1192, 10.1248/cpb.55.1192 Ozpolat, 2003, Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines, Methods Enzymol., 373, 92, 10.1016/S0076-6879(03)73006-7 Suzuki, 1997, Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor, Br. J. Cancer, 76, 83, 10.1038/bjc.1997.340 Kedmi, 2010, The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation, Biomaterials, 31, 9, 10.1016/j.biomaterials.2010.05.027 Moghimi, 2005, Nanomedicine: current status and future prospects, Mol. Target. Polym., 19, 311 Jackson, 2010, Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application, Nat. Rev. Drug Discov., 9, 57, 10.1038/nrd3010